FDA Approves CABOMETYX ™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma

< p > CABOMETYX, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate in a phase 3 trial for patients with advanced RCC, robust and clinically meaningful improvements in all three key efficacy parameters... < /p > < p > 04/25/2016 < /p >
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news